Tag archive for ‘Clal Biotechnology Industries Ltd. (TASE: CBI)’
Koby Yeshayahou On Sunday, December 21st, 2014

Medivation takes up $335 million Curetech licensing option

– The agreement gives Medivation the license to develop and commercialize Curetech’s pidilizumab cancer treatment. –   Medivation has decided to exercise the option granted it by Curetech More...

Gali Weinreb On Wednesday, September 10th, 2014

Investor files class action on Andromeda biotech

– Investor Mori Arkin: If Hyperion overlooked weak points in the data, it’s their mistake. – The Andromeda affair, in which an Israeli company is being accused of forging clinical More...

Gali Weinreb On Monday, September 8th, 2014

Len Blavatnik donates $20 million to Tel Aviv University

– The donation will fund drug development, computer science, cyber research, movie production and more. –   The Blavatnik Family Foundation is donating $20 million to Tel Aviv University More...

Gali Weinreb On Thursday, May 1st, 2014

Novartis abandons plans to buy Israeli stem cell treatment company Gamida Cell

– Novartis had signed an MOU to acquire the stem cell treatment company for up to $600 million. –  Elbit Medical Technologies Ltd. (TASE:EMTC) and Clal Biotechnology Industries Ltd. (TASE: CBI) More...

Israeli Mediwound Begins Trading On Nasdaq

– The burns and wounds treatment developer is issuing 5 million shares at $14 each. – – Burns and wounds treatment developer Mediwound will begin trading on the US Nasdaq market today. Clal More...

Ilan Shavit On Tuesday, March 18th, 2014

Novartis In Advanced Talks to Acquire Israeli Stem Cell Developer Gamida-Cell

– The stem cell developer could be acquired at a company value of hundreds of millions of dollars. – Stem cell therapies developer Gamida-Cell Ltd. has received an acquisition offer from an international pharma More...

health
Koby Yeshayahou On Wednesday, February 26th, 2014

Clal Biotech Selling Diabetes Treatment Co Andromeda

– Clal Biotechnology Industries Ltd. (TASE: CBI) has signed a non-binding letter of intent to sell diabetes treatment developer Andromeda Biotech Ltd. to a US pharmaceutical company for an immediate More...

health
Gali Weinreb On Thursday, February 20th, 2014

Teva Sells Andromeda Diabetes Treatment Stake For $72 Million

– Teva will receive $72 million from future sales or from the proceeds of an exit, if any. Diapep277 Slowing the Progression of Type 1 Diabetes. – Clal Biotechnology Industries Ltd. (TASE: CBI) More...

Gali Weinreb On Monday, February 3rd, 2014

More Israeli Life Sciences Companies Going To Nasdaq

– The burn and wound treatment company MediWound plans to raise $100m on Nasdaq at a $400 million valuation.  – In the coming weeks, several Israeli life sciences companies will examine whether More...

Albert Hecht On Thursday, October 3rd, 2013

Len Blavatnik to delist Clal Industries from the Tel Aviv Stock Exchange (TASE)

– Blavatnik’s Access Industries, which owns 49.9% of Clal Industries, will buy the public’s holdings under an offer to purchase. – – / By Efrat Peretz and Kobi Yeshayahou More...

Wordpress site Developed by Fixing WordPress Problems